Arylazolylthioacetanilide. Part 11: Design, Synthesis and Biological Evaluation of 1,2,4-triazole Thioacetanilide Derivatives as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors

Author(s): Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Yuemao Shen, Xinyong Liu

Journal Name: Medicinal Chemistry

Volume 9 , Issue 7 , 2013

Become EABM
Become Reviewer


A series of novel 1,2,4-triazole thioacetanilide derivatives has been designed, synthesized and evaluated for their anti-HIV activities in MT-4 cells. Half of these compounds showed moderate to potent activities against wild-type HIV-1 with an EC50 ranging from 38.0 μM to 4.08 µM. Among them, 2-(4-(2-fluorobenzyl)-5-isopropyl-4H-1,2,4-triazol- 3-ylthio)-N-(2-nitrophenyl)acetamide 7d was identified as the most promising compound (EC50 = 4.26 µM, SI = 49). However, no compound was active against HIV-2. The preliminary structure-activity relationships among the newly synthesized congeners are discussed.

Keywords: HIV-1, AIDS, NNRTIs, 1, 2, 4-triazole thioacetanilides, Anti-HIV-1 activity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [968 - 973]
Pages: 6
DOI: 10.2174/1573406411309070010
Price: $65

Article Metrics

PDF: 21